Optimising IL-2 for Cancer Immunotherapy

키워드

참고문헌 (129)

1. McCarthy EF, "The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas", Iowa Orthop J, 26, pp.154~158 (2006)
2. Browning CH, "Paul Ehrlich’s Collected Papers", Nature, 189, pp.254~255 (1961)
3. Thomas L, "Cellular and Humoral Aspects of the Hypersensitive States", pp.529~532 (1959), Hoeber-Harper
4. Burnet M, "Cancer; a biological approach. I. The processes of control", BMJ, 1, pp.779~786 (1957)
5. Foley EJ, "Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin", Cancer Res, 13, pp.835~837 (1953)
6. Miller JF, "Immunological function of the thymus", Lancet, 2, pp.748~749 (1961)
7. Cooper MD, "The early history of B cells", Nat Rev Immunol, 15, pp.191~197 (2015)
8. Ribatti D, "The concept of immune surveillance against tumors. The first theories", Oncotarget, 8, pp.7175~7180 (2017)
9. Dunn GP, "Cancer immunoediting : from immunosurveillance to tumor escape", Nat Immunol, 3, pp.991~998 (2002)
10. Smyth MJ, "Cancer immunosurveillance and immunoediting : the roles of immunity in suppressing tumor development and shaping tumor immunogenicity", Adv Immunol, 90, pp.1~50 (2006)
11. Schreiber RD, "Cancer immunoediting : integrating immunity’s roles in cancer suppression and promotion", Science, 331, pp.1565~1570 (2011)
12. O’Sullivan T, "Cancer immunoediting by the innate immune system in the absence of adaptive immunity", J Exp Med, 209, pp.1869~1882 (2012)
13. Voskoboinik I, "Perforin-mediated target-cell death and immune homeostasis", Nat Rev Immunol, 6, pp.940~952 (2006)
14. Raulet DH, "Missing self recognition and self tolerance of natural killer(NK)cells", Semin Immunol, 18, pp.145~150 (2006)
15. Kremenovic M, "Clinical and molecular insights into BCG immunotherapy for melanoma", J Intern Med, 288, pp.625~640 (2020)
16. Ascierto PA, "Adjuvant interferon alfa in malignant melanoma : an interdisciplinary and multinational expert review", Crit Rev Oncol Hematol, 85, pp.149~161 (2013)
17. Craig S, "Ultraviolet light and melanoma", J Pathol, 244, pp.578~585 (2018)
18. Xie N, "Neoantigens : promising targets for cancer therapy", Signal Transduct Target Ther, 8, pp.9~ (2023)
19. Alexandrov LB, "Signatures of mutational processes in human cancer", Nature, 500, pp.415~421 (2013)
20. Raskov H, "Cytotoxic CD8+ T cells in cancer and cancer immunotherapy", Br J Cancer, 124, pp.359~367 (2021)
21. Shourian M, "Common gamma chain cytokines and CD8 T cells in cancer", Semin Immunol, 42, pp.101307~ (2019)
22. Zhang X, "Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15", Immunity, 8, pp.591~599 (1998)
23. Kennedy MK, "Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice", J Exp Med, 191, pp.771~780 (2000)
24. Tan JT, "IL-7 is critical for homeostatic proliferation and survival of naive T cells", Proc Natl Acad Sci U S A, 98, pp.8732~8737 (2001)
25. Judge AD, "Interleukin 15 controls both proliferation and survival of a subset of memory-phenotype CD8+ T cells", J Exp Med, 196, pp.935~946 (2002)
26. Berard M, "IL-15 promotes the survival of naive and memory phenotype CD8+ T cells", J Immunol, 170, pp.5018~5026 (2003)
27. Sprent J, "Normal T cell homeostasis : the conversion of naive cells into memory-phenotype cells", Nat Immunol, 12, pp.478~484 (2011)
28. Lee SW, "Shaping heterogeneity of naive CD8+ T cell pools", Immune Netw, 23, pp.e2~ (2023)
29. Boyman O, "A major histocompatibility complex class I-dependent subset of memory phenotype CD8+ cells", J Exp Med, 203, pp.1817~1825 (2006)
30. Younes SA, "Memory phenotype CD4 T cells undergoing rapid, nonburst-like, cytokine-driven proliferation can be distinguished from antigen-experienced memory cells", PLoS Biol, 9, pp.e1001171~ (2011)
31. Kim KS, "Dietary antigens limit mucosal immunity by inducing regulatory T cells in the small intestine", Science, 351, pp.858~863 (2016)
32. Kawabe T, "Redefining the foreign antigen and self-driven memory CD4+ T-cell compartments via transcriptomic, phenotypic, and functional analyses", Front Immunol, 13, pp.870542~ (2022)
33. Tough DF, "Turnover of naive-and memory-phenotype T cells", J Exp Med, 179, pp.1127~1135 (1994)
34. Ernst B, "The peptide ligands mediating positive selection in the thymus control T cell survival and homeostatic proliferation in the periphery", Immunity, 11, pp.173~181 (1999)
35. Goldrath AW, "Low-affinity ligands for the TCR drive proliferation of mature CD8+ T cells in lymphopenic hosts", Immunity, 11, pp.183~190 (1999)
36. Kieper WC, "Homeostatic expansion and phenotypic conversion of naïve T cells in response to self peptide", MHC ligands, 1999, pp.96, 13306~13311
37. Kieper WC, "A role for TCR affinity in regulating naive T cell homeostasis", J Immunol, 172, pp.40~44 (2004)
38. Min B, "Spontaneous T cell proliferation : a physiologic process to create and maintain homeostatic balance and diversity of the immune system", Front Immunol, 9, pp.547~ (2018)
39. Cho JH, "CD45-mediated control of TCR tuning in naïve and memory CD8+ T cells", Nat Commun, 7, pp.13373~ (2016)
40. Boyman O, "The role of interleukin-2 during homeostasis and activation of the immune system", Nat Rev Immunol, 12, pp.180~190 (2012)
41. Sakaguchi S, "Regulatory T cells and human disease", Annu Rev Immunol, 38, pp.541~566 (2020)
42. Plitas G, "Regulatory T cells in cancer", Annu Rev Cancer Biol, 4, pp.459~477 (2020)
43. Boyman O, "Selective stimulation of T cell subsets with antibody-cytokine immune complexes", Science, 311, pp.1924~1927 (2006)
44. Sadlack B, "Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells", Eur J Immunol, 25, pp.3053~3059 (1995)
45. Kim JM, "Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice", Nat Immunol, 8, pp.191~197 (2007)
46. Chinen T, "A critical role for regulatory T cell-mediated control of inflammation in the absence of commensal microbiota", J Exp Med, 207, pp.2323~2330 (2010)
47. Yi J, "Unregulated antigen-presenting cell activation by T cells breaks self tolerance", Proc Natl Acad Sci U S A, 116, pp.1007~1016 (2019)
48. Owen DL, "Identification of cellular sources of IL-2 needed for regulatory T cell development and homeostasis", J Immunol, 200, pp.3926~3933 (2018)
49. Hemmers S, "IL-2 production by self-reactive CD4 thymocytes scales regulatory T cell generation in the thymus", J Exp Med, 216, pp.2466~2478 (2019)
50. Cho JH, "Unique features of naive CD8+ T cell activation by IL-2", J Immunol, 191, pp.5559~5573 (2013)
51. Cho JH, "An intense form of homeostatic proliferation of naive CD8+ cells driven by IL-2", J Exp Med, 204, pp.1787~1801 (2007)
52. Kieper WC, "Recent immune status determines the source of antigens that drive homeostatic T cell expansion", J Immunol, 174, pp.3158~3163 (2005)
53. Le Saout C, "IL-2 mediates CD4+ T cell help in the breakdown of memory-like CD8+ T cell tolerance under lymphopenic conditions", PLoS One, 5, pp.e12659~ (2010)
54. Kim J, "Spontaneous proliferation of CD4+ T cells in RAG-deficient hosts promotes antigen-independent but IL-2-dependent strong proliferative response of naïve CD8+ T cells", Front Immunol, 9, pp.1907~ (2018)
55. Tough DF, "Induction of bystander T cell proliferation by viruses and type I interferon in vivo", Science, 272, pp.1947~1950 (1996)
56. Waldmann TA, "The biology of interleukin-2 and interleukin-15 : implications for cancer therapy and vaccine design", Nat Rev Immunol, 6, pp.595~601 (2006)
57. Rubinstein MP, "Converting IL-15 to a superagonist by binding to soluble IL-15Rα", Proc Natl Acad Sci U S A, 103, pp.9166~9171 (2006)
58. Stoklasek TA, "Combined IL-15", IL-15Rα immunotherapy maximizes IL-15 activity in vivo, 2006, pp.177, 6072~6080
59. Cho JH, "T cell receptor-dependent regulation of lipid rafts controls naive CD8+ T cell homeostasis", Immunity, 32, pp.214~226 (2010)
60. Jameson SC, "Innate memory T cells", Adv Immunol, 126, pp.173~213 (2015)
61. White JT, "Virtual memory T cells develop and mediate bystander protective immunity in an IL-15-dependent manner", Nat Commun, 7, pp.11291~ (2016)
62. Beura LK, "Normalizing the environment recapitulates adult human immune traits in laboratory mice", Nature, 532, pp.512~516 (2016)
63. Gowans JL, "The route of re-circulation of lymphocytes in the rat", Proc R Soc Lond, B, 159, pp.257~282 (1964)
64. Sprent J, "Role of H-2 gene products in the function of T helper cells from normal and chimeric mice in vivo", Immunol Rev, 42, pp.108~137 (1978)
65. Blattman JN, "Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo", Nat Med, 9, pp.540~547 (2003)
66. Bachmann MF, "Interleukin 2 : from immunostimulation to immunoregulation and back again", EMBO Rep, 8, pp.1142~1148 (2007)
67. Williams MA, "Effector and memory CTL differentiation", Annu Rev Immunol, 25, pp.171~192 (2007)
68. Jameson SC, "Diversity in T cell memory : an embarrassment of riches", Immunity, 31, pp.859~871 (2009)
69. Arens R, "Plasticity in programming of effector and memory CD8 T-cell formation", Immunol Rev, 235, pp.190~205 (2010)
70. Cui W, "Generation of effector CD8+ T cells and their conversion to memory T cells", Immunol Rev, 236, pp.151~166 (2010)
71. Malek TR, "Interleukin-2 receptor signaling : at the interface between tolerance and immunity", Immunity, 33, pp.153~165 (2010)
72. Liao W, "Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy", Immunity, 38, pp.13~25 (2013)
73. Kalia V, "Regulation of effector and memory CD8 T cell differentiation by IL-2-A balancing act", Front Immunol, 9, pp.2987~ (2018)
74. Mathieu C, "IL-2 and IL-15 regulate CD8+ memory T-cell differentiation but are dispensable for protective recall responses", Eur J Immunol, 45, pp.3324~3338 (2015)
75. Decaluwe H, "γc deficiency precludes CD8+ T cell memory despite formation of potent T cell effectors", Proc Natl Acad Sci U S A, 107, pp.9311~9316 (2010)
76. Obar JJ, "Early signals during CD8 T cell priming regulate the generation of central memory cells", J Immunol, 185, pp.263~272 (2010)
77. Kalia V, "Prolonged interleukin-2Rα expression on virus-specific CD8+ T cells favors terminal-effector differentiation in vivo", Immunity, 32, pp.91~103 (2010)
78. Sprent J, "T and B memory cells", Cell, 76, pp.315~322 (1994)
79. Sprent J, "T cell death and memory", Science, 293, pp.245~248 (2001)
80. D’Souza WN, "Cutting edge : latecomer CD8 T cells are imprinted with a unique differentiation program", J Immunol, 177, pp.777~781 (2006)
81. Dong C, "Cytokine regulation and function in T cells", Annu Rev Immunol, 39, pp.51~76 (2021)
82. West EE, "PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells", J Clin Invest, 123, pp.2604~2615 (2013)
83. Beltra JC, "IL2Rβ-dependent signals drive terminal exhaustion and suppress memory development during chronic viral infection", Proc Natl Acad Sci U S A, 113, pp.E5444~ (2016)
84. Kahan SM, "Intrinsic IL-2 production by effector CD8 T cells affects IL-2 signaling and promotes fate decisions, stemness, and protection", Sci Immunol, 7, pp.eabl6322~ (2022)
85. Matloubian M, "CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection", J Virol, 68, pp.8056~8063 (1994)
86. Krieg C, "Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells", Proc Natl Acad Sci U S A, 107, pp.11906~11911 (2010)
87. Jhunjhunwala S, "Antigen presentation in cancer : insights into tumour immunogenicity and immune evasion", Nat Rev Cancer, 21, pp.298~312 (2021)
88. Ashby KM, "A guide to thymic selection of T cells", Nat Rev Immunol (2023)
89. Pulendran B, "Emerging concepts in the science of vaccine adjuvants", Nat Rev Drug Discov, 20, pp.454~475 (2021)
90. West AP, "Mitochondrial DNA in innate immune responses and inflammatory pathology", Nat Rev Immunol, 17, pp.363~375 (2017)
91. Huang PW, "Immune checkpoint inhibitors win the 2018 Nobel Prize", Biomed J, 42, pp.299~306 (2019)
92. Perdyan A, "The effectiveness of cancer immune checkpoint inhibitor retreatment and rechallenge-a systematic review", Cancers(Basel), 15, pp.3490~ (2023)
93. Dwyer CJ, "Fueling cancer immunotherapy with common gamma chain cytokines", Front Immunol, 10, pp.263~ (2019)
94. Raeber ME, "The role of cytokines in T-cell memory in health and disease", Immunol Rev, 283, pp.176~193 (2018)
95. Smith KA, "T-cell growth factor and the culture of cloned functional T cells", Adv Immunol, 31, pp.137~175 (1981)
96. Rosenberg SA, "IL-2 : the first effective immunotherapy for human cancer", J Immunol, 192, pp.5451~5458 (2014)
97. Létourneau S, "IL-2", anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor α subunit CD25, 2010, pp.107, 2171~2176
98. Spangler JB, "Antibodies to interleukin-2 elicit selective T cell subset potentiation through distinct conformational mechanisms", Immunity, 42, pp.815~825 (2015)
99. Arenas-Ramirez N, "Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2", Sci Transl Med, 8, pp.367~ (2016)
100. Lee JY, "TCB2, a new anti-human interleukin-2 antibody, facilitates heterodimeric IL-2 receptor signaling and improves anti-tumor immunity", OncoImmunology, 9, pp.1681869~ (2019)
101. Zingg D, "The histone methyltransferase Ezh2 controls mechanisms of adaptive resistance to tumor immunotherapy", Cell Reports, 20, pp.854~867 (2017)
102. Raeber ME, "Interleukin-2 signals converge in a lymphoid-dendritic cell pathway that promotes anticancer immunity", Sci Transl Med, 12, pp.eaba5464~ (2020)
103. Webster KE, "In vivo expansion of Treg cells with IL-2-mAb complexes : induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression", J Exp Med, 206, pp.751~760 (2009)
104. Pilat N, "Treg-mediated prolonged survival of skin allografts without immunosuppression", Proc Natl Acad Sci U S A, 116, pp.13508~13516 (2019)
105. Yamada Y, "Biased IL-2 signals induce Foxp3-rich pulmonary lymphoid structures and facilitate long-term lung allograft acceptance in mice", Nat Commun, 14, pp.1383~ (2023)
106. Pilat N, "Treg therapies revisited : tolerance beyond deletion", Front Immunol, 11, pp.622810~ (2021)
107. Carmenate T, "Human IL-2 mutein with higher antitumor efficacy than wild type IL-2", J Immunol, 190, pp.6230~6238 (2013)
108. Silva DA, "De novo design of potent and selective mimics of IL-2 and IL-15", Nature, 565, pp.186~191 (2019)
109. Levin AM, "Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’", Nature, 484, pp.529~533 (2012)
110. Merchant R, "Fine-tuned long-acting interleukin-2 superkine potentiates durable immune responses in mice and non-human primate", J Immunother Cancer, 10, pp.e003155~ (2022)
111. Sahin D, "An IL-2-grafted antibody immunotherapy with potent efficacy against metastatic cancer", Nat Commun, 11, pp.6440~ (2020)
112. Lopes JE, "ALKS 4230 : a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy", J Immunother Cancer, 8, pp.e000673~ (2020)
113. Charych DH, "NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models", Clin Cancer Res, 22, pp.680~690 (2016)
114. Sznol M, "Teaching an old dog new tricks : re-engineering IL-2 for immuno-oncology applications", J Immunother Cancer, 11, pp.e006346~ (2023)
115. Raeber ME, "Interleukin-2-based therapies in cancer", Sci Transl Med, 14, pp.eabo5409~ (2022)
116. Raeber ME, "A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases", EBioMedicine, 90, pp.104539~ (2023)
117. Hashimoto M, "PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program", Nature, 610, pp.173~181 (2022)
118. Codarri Deak L, "PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells", Nature, 610, pp.161~172 (2022)
119. Tichet M, "Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8+ T cells and reprogramming macrophages", Immunity, 56, pp.162~179 (2023)
120. Ren Z, "Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity", J Clin Invest, 132, pp.e153604~ (2022)
121. Wu W, "IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells", Nat Can, 4, pp.1309~1325 (2023)
122. Mo F, "An engineered IL-2 partial agonist promotes CD8+ T cell stemness", Nature, 597, pp.544~548 (2021)
123. Guan Q, "Strategies to reinvigorate exhausted CD8+ T cells in tumor microenvironment", Front Immunol, 14, pp.1204363~ (2023)
124. Muhammad S, "Reigniting hope in cancer treatment : the promise and pitfalls of IL-2 and IL-2R targeting strategies", Mol Cancer, 22, pp.121~ (2023)
125. Li Y, "Regulatory T cells control toxicity in a humanized model of IL-2 therapy", Nat Commun, 8, pp.1762~ (2017)
126. Smith C, "Differential outcome of IL-2", anti-IL-2 complex therapy on effector and memory CD8+ T cells following vaccination with an adenoviral vector encoding EBV epitopes, 2011, pp.186, 5784~5790
127. Tsyklauri O, "Regulatory T cells suppress the formation of potent KLRK1 and IL-7R expressing effector CD8 T cells by limiting IL-2", eLife, 12, pp.e79342~ (2023)
128. Xu Y, "An engineered IL15 cytokine mutein fused to an anti-PD1 improves intratumoral T-cell function and antitumor immunity", Cancer Immunol Res, 9, pp.1141~1157 (2021)
129. Shen J, "An engineered concealed IL-15-R elicits tumor-specific CD8+T cell responses through PD-1-cis delivery", J Exp Med, 219, pp.e20220745~ (2022)

관련 논문AI추천